JP2018154569A - Agent for suppressing enlargement of lipid droplets in liver, composition for suppressing enlargement of lipid droplets in liver and food composition for suppressing enlargement of fat droplets in liver - Google Patents
Agent for suppressing enlargement of lipid droplets in liver, composition for suppressing enlargement of lipid droplets in liver and food composition for suppressing enlargement of fat droplets in liver Download PDFInfo
- Publication number
- JP2018154569A JP2018154569A JP2017050740A JP2017050740A JP2018154569A JP 2018154569 A JP2018154569 A JP 2018154569A JP 2017050740 A JP2017050740 A JP 2017050740A JP 2017050740 A JP2017050740 A JP 2017050740A JP 2018154569 A JP2018154569 A JP 2018154569A
- Authority
- JP
- Japan
- Prior art keywords
- liver
- arctigenin
- enlargement
- composition
- lipid droplets
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000002632 lipids Chemical class 0.000 title claims abstract description 46
- 210000004185 liver Anatomy 0.000 title claims abstract description 37
- 239000000203 mixture Substances 0.000 title claims description 54
- 235000013305 food Nutrition 0.000 title claims description 29
- NQWVSMVXKMHKTF-JKSUJKDBSA-N (-)-Arctigenin Chemical compound C1=C(OC)C(OC)=CC=C1C[C@@H]1[C@@H](CC=2C=C(OC)C(O)=CC=2)C(=O)OC1 NQWVSMVXKMHKTF-JKSUJKDBSA-N 0.000 claims abstract description 53
- YYGRXNOXOVZIKE-UHFFFAOYSA-N Arctigenin Natural products COC1CCC(CC2COC(=O)C2CC3CCC(O)C(C3)OC)CC1OC YYGRXNOXOVZIKE-UHFFFAOYSA-N 0.000 claims abstract description 53
- OIFFJDGSLVHPCW-UHFFFAOYSA-N Guayarol Natural products COc1ccc(CC2C(Cc3ccc(O)c(O)c3)COC2=O)cc1OC OIFFJDGSLVHPCW-UHFFFAOYSA-N 0.000 claims abstract description 53
- NQWVSMVXKMHKTF-UHFFFAOYSA-N L-Arctigenin Natural products C1=C(OC)C(OC)=CC=C1CC1C(CC=2C=C(OC)C(O)=CC=2)C(=O)OC1 NQWVSMVXKMHKTF-UHFFFAOYSA-N 0.000 claims abstract description 53
- NWFYESYCEQICQP-UHFFFAOYSA-N methylmatairesinol Natural products C1=C(OC)C(OC)=CC=C1CC1C(=O)OCC1CC1=CC=C(O)C(OC)=C1 NWFYESYCEQICQP-UHFFFAOYSA-N 0.000 claims abstract description 53
- XOJVHLIYNSOZOO-SWOBOCGESA-N Arctiin Chemical compound C1=C(OC)C(OC)=CC=C1C[C@@H]1[C@@H](CC=2C=C(OC)C(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O)=CC=2)C(=O)OC1 XOJVHLIYNSOZOO-SWOBOCGESA-N 0.000 claims abstract description 37
- BPYGTFFYYOWDBC-LOVSFRALSA-N arctiin Natural products COc1ccc(C[C@H]2COC(=O)[C@@H]2Cc3ccc(O[C@@H]4O[C@H](C)[C@@H](O)[C@H](O)[C@H]4O)c(OC)c3)cc1OC BPYGTFFYYOWDBC-LOVSFRALSA-N 0.000 claims abstract description 37
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 23
- 102000004311 liver X receptors Human genes 0.000 claims abstract description 16
- 108090000865 liver X receptors Proteins 0.000 claims abstract description 16
- 239000004480 active ingredient Substances 0.000 claims abstract description 14
- 239000000284 extract Substances 0.000 claims description 61
- 235000003130 Arctium lappa Nutrition 0.000 claims description 49
- 235000008078 Arctium minus Nutrition 0.000 claims description 49
- 239000003112 inhibitor Substances 0.000 claims description 17
- 241000555712 Forsythia Species 0.000 claims description 10
- 230000002401 inhibitory effect Effects 0.000 claims description 6
- 241000208843 Arctium Species 0.000 claims 6
- 239000008280 blood Substances 0.000 abstract description 14
- 210000004369 blood Anatomy 0.000 abstract description 14
- 210000005228 liver tissue Anatomy 0.000 abstract description 12
- 108010039731 Fatty Acid Synthases Proteins 0.000 abstract description 11
- 239000003814 drug Substances 0.000 abstract description 10
- 108090000623 proteins and genes Proteins 0.000 abstract description 10
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 abstract description 8
- 235000021588 free fatty acids Nutrition 0.000 abstract description 6
- 230000003247 decreasing effect Effects 0.000 abstract description 5
- 230000002950 deficient Effects 0.000 abstract description 3
- 229940079593 drug Drugs 0.000 abstract description 3
- 102000005861 leptin receptors Human genes 0.000 abstract description 3
- 108010019813 leptin receptors Proteins 0.000 abstract description 3
- 102000015303 Fatty Acid Synthases Human genes 0.000 abstract 1
- 230000001105 regulatory effect Effects 0.000 abstract 1
- 240000005528 Arctium lappa Species 0.000 description 52
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 25
- 208000004930 Fatty Liver Diseases 0.000 description 23
- 208000010706 fatty liver disease Diseases 0.000 description 21
- 206010019708 Hepatic steatosis Diseases 0.000 description 20
- 231100000240 steatosis hepatitis Toxicity 0.000 description 20
- 241000196324 Embryophyta Species 0.000 description 18
- 108010020396 Sterol Regulatory Element Binding Proteins Proteins 0.000 description 17
- 102000009822 Sterol Regulatory Element Binding Proteins Human genes 0.000 description 16
- 239000000843 powder Substances 0.000 description 15
- 239000003925 fat Substances 0.000 description 14
- 206010020880 Hypertrophy Diseases 0.000 description 13
- 239000008187 granular material Substances 0.000 description 13
- 102000004190 Enzymes Human genes 0.000 description 11
- 108090000790 Enzymes Proteins 0.000 description 11
- 235000019441 ethanol Nutrition 0.000 description 11
- 102100022089 Acyl-[acyl-carrier-protein] hydrolase Human genes 0.000 description 10
- 230000000694 effects Effects 0.000 description 10
- 238000002360 preparation method Methods 0.000 description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 10
- 239000004375 Dextrin Substances 0.000 description 9
- 229920001353 Dextrin Polymers 0.000 description 9
- 235000019425 dextrin Nutrition 0.000 description 9
- 239000000243 solution Substances 0.000 description 9
- 102000000452 Acetyl-CoA carboxylase Human genes 0.000 description 7
- 108010016219 Acetyl-CoA carboxylase Proteins 0.000 description 7
- 108010018763 Biotin carboxylase Proteins 0.000 description 7
- 102000051325 Glucagon Human genes 0.000 description 7
- 108060003199 Glucagon Proteins 0.000 description 7
- 241001465754 Metazoa Species 0.000 description 7
- 238000006243 chemical reaction Methods 0.000 description 7
- 238000000605 extraction Methods 0.000 description 7
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 description 7
- 229960004666 glucagon Drugs 0.000 description 7
- 239000007788 liquid Substances 0.000 description 7
- 239000003960 organic solvent Substances 0.000 description 7
- 239000003826 tablet Substances 0.000 description 7
- 206010016654 Fibrosis Diseases 0.000 description 6
- 230000007882 cirrhosis Effects 0.000 description 6
- 208000019425 cirrhosis of liver Diseases 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 201000007270 liver cancer Diseases 0.000 description 6
- 208000014018 liver neoplasm Diseases 0.000 description 6
- 238000004519 manufacturing process Methods 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- 239000007787 solid Substances 0.000 description 6
- 238000010438 heat treatment Methods 0.000 description 5
- 230000002829 reductive effect Effects 0.000 description 5
- 238000003756 stirring Methods 0.000 description 5
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 4
- 108010010803 Gelatin Proteins 0.000 description 4
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 4
- 239000002537 cosmetic Substances 0.000 description 4
- 235000013399 edible fruits Nutrition 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 239000008273 gelatin Substances 0.000 description 4
- 229920000159 gelatin Polymers 0.000 description 4
- 235000019322 gelatine Nutrition 0.000 description 4
- 235000011852 gelatine desserts Nutrition 0.000 description 4
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 4
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 238000010992 reflux Methods 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 230000001629 suppression Effects 0.000 description 4
- IFBHRQDFSNCLOZ-UHFFFAOYSA-N 2-(hydroxymethyl)-6-(4-nitrophenoxy)oxane-3,4,5-triol Chemical compound OC1C(O)C(O)C(CO)OC1OC1=CC=C([N+]([O-])=O)C=C1 IFBHRQDFSNCLOZ-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 208000007082 Alcoholic Fatty Liver Diseases 0.000 description 3
- 206010003210 Arteriosclerosis Diseases 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 241000286209 Phasianidae Species 0.000 description 3
- 238000002835 absorbance Methods 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 208000026594 alcoholic fatty liver disease Diseases 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 208000011775 arteriosclerosis disease Diseases 0.000 description 3
- 102000006995 beta-Glucosidase Human genes 0.000 description 3
- 108010047754 beta-Glucosidase Proteins 0.000 description 3
- 229920002678 cellulose Polymers 0.000 description 3
- 239000001913 cellulose Substances 0.000 description 3
- 235000010980 cellulose Nutrition 0.000 description 3
- 239000003086 colorant Substances 0.000 description 3
- 210000003494 hepatocyte Anatomy 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 description 3
- 239000012488 sample solution Substances 0.000 description 3
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 2
- 239000001856 Ethyl cellulose Substances 0.000 description 2
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 238000011529 RT qPCR Methods 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 238000000692 Student's t-test Methods 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- 102000040945 Transcription factor Human genes 0.000 description 2
- 108091023040 Transcription factor Proteins 0.000 description 2
- 244000098338 Triticum aestivum Species 0.000 description 2
- 239000000853 adhesive Substances 0.000 description 2
- 230000001070 adhesive effect Effects 0.000 description 2
- 239000000443 aerosol Substances 0.000 description 2
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 2
- 229910052782 aluminium Inorganic materials 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 239000012490 blank solution Substances 0.000 description 2
- 229910000019 calcium carbonate Inorganic materials 0.000 description 2
- 235000010216 calcium carbonate Nutrition 0.000 description 2
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 235000008504 concentrate Nutrition 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 239000007884 disintegrant Substances 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 235000019325 ethyl cellulose Nutrition 0.000 description 2
- 229920001249 ethyl cellulose Polymers 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 230000004136 fatty acid synthesis Effects 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 239000007902 hard capsule Substances 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical group N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 239000005001 laminate film Substances 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000002335 preservative effect Effects 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 235000021067 refined food Nutrition 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- -1 tics Substances 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- DRCWOKJLSQUJPZ-DZGCQCFKSA-N (4ar,9as)-n-ethyl-1,4,9,9a-tetrahydrofluoren-4a-amine Chemical compound C1C2=CC=CC=C2[C@]2(NCC)[C@H]1CC=CC2 DRCWOKJLSQUJPZ-DZGCQCFKSA-N 0.000 description 1
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- 108020004463 18S ribosomal RNA Proteins 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- BTJIUGUIPKRLHP-UHFFFAOYSA-N 4-nitrophenol Chemical compound OC1=CC=C([N+]([O-])=O)C=C1 BTJIUGUIPKRLHP-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 240000001592 Amaranthus caudatus Species 0.000 description 1
- 235000009328 Amaranthus caudatus Nutrition 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 241000219195 Arabidopsis thaliana Species 0.000 description 1
- 235000007319 Avena orientalis Nutrition 0.000 description 1
- 244000075850 Avena orientalis Species 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 244000020518 Carthamus tinctorius Species 0.000 description 1
- 235000003255 Carthamus tinctorius Nutrition 0.000 description 1
- 229920000623 Cellulose acetate phthalate Polymers 0.000 description 1
- 240000004385 Centaurea cyanus Species 0.000 description 1
- 235000005940 Centaurea cyanus Nutrition 0.000 description 1
- 241000132536 Cirsium Species 0.000 description 1
- 241000725101 Clea Species 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 241000208296 Datura Species 0.000 description 1
- 208000032928 Dyslipidaemia Diseases 0.000 description 1
- 239000004278 EU approved seasoning Substances 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- 206010016262 Fatty liver alcoholic Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 244000196755 Hesperocyparis lusitanica Species 0.000 description 1
- 101001008429 Homo sapiens Nucleobindin-2 Proteins 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 241000758791 Juglandaceae Species 0.000 description 1
- 208000017170 Lipid metabolism disease Diseases 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- CERQOIWHTDAKMF-UHFFFAOYSA-N Methacrylic acid Chemical compound CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 description 1
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 244000187664 Nerium oleander Species 0.000 description 1
- 108020005497 Nuclear hormone receptor Proteins 0.000 description 1
- 102100027441 Nucleobindin-2 Human genes 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 244000131316 Panax pseudoginseng Species 0.000 description 1
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 1
- 235000003140 Panax quinquefolius Nutrition 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 244000059026 Prunus jamasakura Species 0.000 description 1
- 235000013946 Prunus jamasakura Nutrition 0.000 description 1
- 244000272911 Salacia chinensis Species 0.000 description 1
- 241000647991 Salacia reticulata Species 0.000 description 1
- 229920001800 Shellac Polymers 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- 241001414989 Thysanoptera Species 0.000 description 1
- 244000111306 Torreya nucifera Species 0.000 description 1
- 235000006732 Torreya nucifera Nutrition 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 241000376294 Tringa semipalmata Species 0.000 description 1
- 235000021307 Triticum Nutrition 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000008351 acetate buffer Substances 0.000 description 1
- VJHCJDRQFCCTHL-UHFFFAOYSA-N acetic acid 2,3,4,5,6-pentahydroxyhexanal Chemical compound CC(O)=O.OCC(O)C(O)C(O)C(O)C=O VJHCJDRQFCCTHL-UHFFFAOYSA-N 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 239000004178 amaranth Substances 0.000 description 1
- 235000012735 amaranth Nutrition 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000000305 astragalus gummifer gum Substances 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 230000008033 biological extinction Effects 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 239000006189 buccal tablet Substances 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 238000010804 cDNA synthesis Methods 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 235000011132 calcium sulphate Nutrition 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 229940105329 carboxymethylcellulose Drugs 0.000 description 1
- 229940084030 carboxymethylcellulose calcium Drugs 0.000 description 1
- 229950008138 carmellose Drugs 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 229940081734 cellulose acetate phthalate Drugs 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000007910 chewable tablet Substances 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 238000010411 cooking Methods 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 238000001784 detoxification Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 235000015897 energy drink Nutrition 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 235000011194 food seasoning agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 235000013611 frozen food Nutrition 0.000 description 1
- 235000013569 fruit product Nutrition 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 235000013376 functional food Nutrition 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 235000008434 ginseng Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 210000004209 hair Anatomy 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 239000008172 hydrogenated vegetable oil Substances 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 229920003132 hydroxypropyl methylcellulose phthalate Polymers 0.000 description 1
- 229940031704 hydroxypropyl methylcellulose phthalate Drugs 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 229930013686 lignan Natural products 0.000 description 1
- 235000009408 lignans Nutrition 0.000 description 1
- 150000005692 lignans Chemical class 0.000 description 1
- 235000021056 liquid food Nutrition 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 229960003511 macrogol Drugs 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 238000001000 micrograph Methods 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 210000000282 nail Anatomy 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 102000006255 nuclear receptors Human genes 0.000 description 1
- 108020004017 nuclear receptors Proteins 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 210000003463 organelle Anatomy 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 229920001289 polyvinyl ether Polymers 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 235000013324 preserved food Nutrition 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 235000020991 processed meat Nutrition 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 150000004671 saturated fatty acids Chemical class 0.000 description 1
- 210000004761 scalp Anatomy 0.000 description 1
- 239000004208 shellac Substances 0.000 description 1
- 229940113147 shellac Drugs 0.000 description 1
- 235000013874 shellac Nutrition 0.000 description 1
- ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000012089 stop solution Substances 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000007940 sugar coated tablet Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 235000020234 walnut Nutrition 0.000 description 1
Landscapes
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Description
本発明は、肝臓の脂肪滴の肥大化を抑制する作用を有する薬剤、組成物および食品組成物に関する。 The present invention relates to a drug, a composition and a food composition having an action of suppressing enlargement of lipid droplets in the liver.
肝臓は、小腸で吸収された脂質を脂肪酸に分解し、脂肪酸から中性脂肪を合成してエネルギー源として肝細胞中に蓄積する。しかし、エネルギーとして使用されるよりも蓄積される脂肪が多いと、肝細胞に脂肪が溜まってしまう。全肝細胞の30%以上が脂肪化した状態を脂肪肝という。 The liver breaks down lipids absorbed in the small intestine into fatty acids, synthesizes neutral fats from the fatty acids and accumulates them in the hepatocytes as an energy source. However, if more fat is accumulated than is used as energy, fat accumulates in hepatocytes. A state in which 30% or more of all hepatocytes are fattened is called fatty liver.
脂肪肝となる原因の1つとして、飲酒がある。アルコールは、肝臓で解毒されて体外に排出されるが、解毒の過程で肝臓の働きに異常が生じると、肝臓中に脂肪が蓄積してしまうことがある。飲酒が原因でできる脂肪肝は、アルコール性脂肪肝と呼ばれる。また、肥満、糖尿病および脂質異常症(高脂血症)などによりインスリンの働きが低下して脂肪肝となることがある。このような脂肪肝は、非アルコール性脂肪肝と呼ばれる。 One of the causes of fatty liver is drinking alcohol. Alcohol is detoxified by the liver and excreted from the body, but if abnormalities occur in the liver function during the detoxification process, fat may accumulate in the liver. Fatty liver caused by drinking is called alcoholic fatty liver. Also, obesity, diabetes, dyslipidemia (hyperlipidemia), etc., may reduce insulin function and cause fatty liver. Such fatty liver is called non-alcoholic fatty liver.
脂肪肝は、動脈硬化などの様々な生活習慣病を引き起こすおそれがある。また、脂肪肝は、脂肪性肝炎(アルコール性脂肪性肝炎(ASH)および非アルコール性脂肪性肝炎(NASH)など)となることがあり、さらに肝硬変や肝がんなどに進行することもある。 Fatty liver can cause various lifestyle-related diseases such as arteriosclerosis. In addition, fatty liver may become steatohepatitis (such as alcoholic steatohepatitis (ASH) and nonalcoholic steatohepatitis (NASH)), and may progress to cirrhosis or liver cancer.
脂肪肝を抑制する方法として、特許文献1には、サラシア・レティキュラータおよびサラシア・キネンシスから選択される少なくとも一方の根部の抽出物を有効成分として含むことを特徴とする脂肪肝抑制剤が開示されている。 As a method for suppressing fatty liver, Patent Document 1 discloses a fatty liver inhibitor characterized by containing, as an active ingredient, an extract of at least one root selected from Salacia reticulata and Salacia chinensis. Yes.
上述したように、脂肪肝は、様々な生活習慣病を引き起こしたり、肝硬変や肝がんに進行したりするおそれがあるため、脂肪肝を効率的に抑制できる薬剤の開発が望まれている。本発明は、肝臓における脂肪滴の肥大化を抑制することが可能な新規の薬剤を提供することを目的とする。 As described above, since fatty liver may cause various lifestyle-related diseases or progress to cirrhosis or liver cancer, development of a drug capable of efficiently suppressing fatty liver is desired. An object of this invention is to provide the novel chemical | medical agent which can suppress the enlargement of the lipid droplet in a liver.
本発明者らは、アルクチゲニンを投与したレプチン受容体欠損モデルマウスの血中トリグリセリドおよび遊離脂肪酸の濃度がControl群と比較して減少することを見出した。そこで、肝臓組織を顕微鏡観察したところ、アルクチゲニン投与群(AG群)では、Control群と比較して脂肪滴が小さく、また数が少ないことを見出した。さらに、AG群では、Control群と比較して脂肪酸合成酵素の発現を制御するLXRαおよびSREBP1cをコードする遺伝子の発現量が減少していることを見出し、本発明を完成させた。 The inventors of the present invention have found that the blood triglyceride and free fatty acid concentrations of leptin receptor-deficient model mice administered with arctigenin are decreased compared to the control group. Therefore, when the liver tissue was observed with a microscope, it was found that the argigeninin-administered group (AG group) had smaller lipid droplets and a smaller number than the Control group. Furthermore, in the AG group, it was found that the expression levels of genes encoding LXRα and SREBP1c that control the expression of fatty acid synthase were reduced compared to the Control group, and the present invention was completed.
本発明は、アルクチゲニンおよび/またはアルクチインを有効成分として含有する、肝臓の脂肪滴の肥大化抑制剤を提供する。 The present invention provides an agent for suppressing enlargement of liver lipid droplets, which contains arctigenin and / or arctiin as an active ingredient.
また本発明は、アルクチゲニンおよび/またはアルクチインを有効成分として含有する、肝臓の脂肪滴の肥大化抑制用組成物を提供する。 The present invention also provides a composition for suppressing enlargement of lipid droplets in the liver, which contains arctigenin and / or arctiin as an active ingredient.
また本発明は、アルクチゲニンおよび/またはアルクチインを、ゴボウ、ゴボウシ、ゴボウスプラウトもしくはレンギョウまたはこれらの抽出物として含有する、上記肝臓の脂肪滴の肥大化抑制用組成物を提供する。 The present invention also provides the composition for suppressing the enlargement of lipid droplets in the liver, which contains arctigenin and / or arctiin as burdock, burdock, burdock sprout or forsythia or an extract thereof.
また本発明は、アルクチゲニンおよび/またはアルクチインを有効成分として含有する、肝臓の脂肪滴の肥大化抑制用食品組成物を提供する。 The present invention also provides a food composition for suppressing enlargement of lipid droplets in the liver, which contains arctigenin and / or arctiin as an active ingredient.
また本発明は、アルクチゲニンおよび/またはアルクチインを、ゴボウ、ゴボウシ、ゴボウスプラウトもしくはレンギョウまたはこれらの抽出物として含有する、上記肝臓の脂肪滴の肥大化抑制用食品組成物を提供する。 The present invention also provides the above-mentioned food composition for suppressing the enlargement of lipid droplets in the liver, which contains arctigenin and / or arcticin as burdock, burdock, burdock sprout or forsythia or an extract thereof.
また本発明は、アルクチゲニンおよび/またはアルクチインを有効成分として含有する、LXRαまたはSREBP1cの発現抑制剤を提供する。 The present invention also provides an expression inhibitor of LXRα or SREBP1c, which contains arctigenin and / or arctiin as an active ingredient.
本発明は、肝臓における脂肪滴の肥大化を効果的に抑制することができるため、脂肪肝や、脂肪肝に由来する様々な生活習慣病、肝硬変および肝がんなどを治療、予防または改善することができる。 Since the present invention can effectively suppress the enlargement of lipid droplets in the liver, it treats, prevents or improves fatty liver, various lifestyle-related diseases derived from fatty liver, cirrhosis and liver cancer, etc. be able to.
本発明は、アルクチゲニンおよび/またはアルクチインを有効成分として含有する、肝臓の脂肪滴の肥大化抑制剤および肥大化抑制用組成物を提供する。 The present invention provides an agent for suppressing enlargement of lipid droplets in the liver and a composition for inhibiting enlargement, which contain arctigenin and / or arctiin as an active ingredient.
本明細書において、「脂肪滴」とは、トリグリセリドおよびコレステロールなどの脂質を貯蔵する細胞小器官をいう。本明細書において「脂肪滴の肥大化を抑制する」とは、たとえば、細胞における所定の大きさ以上の脂肪滴の数を減少させること、細胞内の各脂肪滴の面積の平均値を減少させることおよび個体中の最大の脂肪滴の面積の平均値を減少させることなどを意味する。 As used herein, “fat droplet” refers to an organelle that stores lipids such as triglycerides and cholesterol. In the present specification, “suppressing fat droplet enlargement” means, for example, reducing the number of lipid droplets having a predetermined size or more in a cell, or reducing the average value of the area of each lipid droplet in the cell. And reducing the average value of the area of the largest lipid droplet in an individual.
本発明の肝臓の脂肪滴の肥大化抑制剤および肥大化抑制用組成物は、アルクチゲニンおよび/またはアルクチインを有効成分として含有する。アルクチゲニンおよびアルクチインは、ゴボウ等の植物に含まれるジフェニルプロパノイド(リグナン類)の1つである。アルクチインは、アルクチゲニンの前駆体であり、生体内で代謝されてアルクチゲニンになることが知られている。アルクチゲニンおよび/またはアルクチインとして、化学的に合成したアルクチゲニンおよび/またはアルクチインを用いてもよいし、植物から単離したアルクチゲニンおよび/またはアルクチインを用いてもよい。また、アルクチゲニンおよび/またはアルクチインとして、アルクチゲニンおよび/またはアルクチインを含む植物そのものまたはこの植物の抽出物を用いてもよい。アルクチゲニンおよび/またはアルクチインを含む植物には、たとえばゴボウ(スプラウト・葉・根茎・ゴボウシ)、アイノコレンギョウ(花・葉・果実・根茎)、チョウセンレンギョウ(花・葉・果実・根茎)、レンギョウ(花・葉・果実・根茎)、シナレンギョウ(花・葉・果実・根茎)、ベニバナ、ヤグルマギク、アメリカオニアザミ、サントリソウ(ギバナアザミ)、カルドン、ゴロツキアザミ、アニウロコアザミ、ゴマ、モミジヒルガオ、シンチクヒメハギ、チョウセンテイカカズラ、テイカカズラ、ムニンテイカカズラ、ヒメテイカカズラ、トウキョウチクトウ、ケテイカカズラ、リョウカオウ、オオケタデ、ヤマザクラ、シロイヌナズナ、アマランス、クルミ、エンバク、スペルタコムギ、軟質コムギ、メキシコイトスギおよびカヤが含まれる。なかでも、ゴボウ(特にゴボウシおよびゴボウスプラウト)およびレンギョウ(特に葉)は、アルクチゲニンおよび/またはアルクチインの含有量が高いため好ましい。植物そのものを用いる場合、生または乾燥して刻んだもの、或いは乾燥して粉末としたものを用いることができる。 The liver fat droplet hypertrophy inhibitor and the hypertrophy suppression composition of the present invention contain arctigenin and / or arctiin as active ingredients. Arctigenin and arctiin are one of diphenylpropanoids (lignans) contained in plants such as burdock. Arctiin is a precursor of arctigenin, and is known to be metabolized in vivo to become arctigenin. As arctigenin and / or arctiin, chemically synthesized arctigenin and / or arctiin may be used, or arctigenin and / or arctiin isolated from a plant may be used. In addition, as arctigenin and / or arctiin, a plant itself containing arctigenin and / or arctiin or an extract of this plant may be used. Plants containing arctigenin and / or arctiin include, for example, burdock (sprouts, leaves, rhizomes, burdock), ayoko forsythia (flowers, leaves, fruits, rhizomes), ginseng (flowers, leaves, fruits, rhizomes), forsythia (flowers)・ Leaf / fruits / rhizome), syringen (flowers / leaves / fruits / rhizome), safflower, cornflower, red-eared thistle, red-eared thrips Datura quail, Teika quail, Muntei casserole, Himeteka quail, Tokyo oleander, Kuteika casserole, Ryo kaiou, Ookade, Yamazakura, Arabidopsis thaliana, Amaranth, walnuts, oats, spelled wheat, soft wheat, Mexican cypress Kaya is included. Of these, burdock (especially burdock and burdock sprout) and forsythia (especially leaves) are preferred because of their high content of arctigenin and / or arctiin. When using the plant itself, raw or dried chopped or dried and powdered can be used.
アルクチゲニンおよび/またはアルクチインとして植物の抽出物を用いる場合、抽出物は、たとえば以下の方法によって植物から調製してもよい。本発明において使用される抽出物は、たとえばアルクチゲニンおよび/またはアルクチインを含む植物から、酵素変換工程および有機溶媒による抽出工程の2段階により抽出してもよい。 When using a plant extract as arctigenin and / or arctiin, the extract may be prepared from the plant by, for example, the following method. The extract used in the present invention may be extracted from a plant containing, for example, arctigenin and / or arctiin by two steps, an enzyme conversion step and an extraction step with an organic solvent.
酵素変換工程は、植物に内在する酵素であるβ-グルコシダーゼにより、該植物に含まれているアルクチインをアルクチゲニンに酵素変換する工程である。具体的には、植物を乾燥し切栽したものを適切な温度に保持することにより内在のβ-グルコシダーゼを作用させて、アルクチインからアルクチゲニンへの反応を進行させる。たとえば、切裁した植物に水などの任意の溶液を加えて、30℃付近の温度(20〜50℃)の間にて攪拌することなどにより、植物を任意の温度に保持することができる。 The enzyme conversion step is a step of enzymatic conversion of arctiin contained in the plant into arctigenin by β-glucosidase, which is an enzyme inherent in the plant. Specifically, a plant obtained by drying and cutting a plant is maintained at an appropriate temperature to cause an endogenous β-glucosidase to act, thereby causing a reaction from arctiin to arctigenin. For example, the plant can be maintained at an arbitrary temperature by adding an arbitrary solution such as water to the cut plant and stirring between temperatures around 30 ° C. (20 to 50 ° C.).
有機溶媒による抽出工程は、任意の適切な有機溶媒を使用して、植物からアルクチゲニンおよびアルクチインを抽出する工程である。すなわち、上記の酵素変換工程によりアルクチゲニンが高含量となった状態で、適切な溶媒を添加して、植物から抽出物(エキス)を抽出する工程である。たとえば、植物に適切な溶媒を添加して、適切な時間加熱攪拌して抽出物を抽出する。また、加熱攪拌以外にも、加熱還流、ドリップ式抽出、浸漬式抽出または加圧式抽出法などの当業者に公知の任意の抽出法を使用して、抽出物を抽出することができる。 The extraction step with an organic solvent is a step of extracting arctigenin and arcthiin from a plant using any appropriate organic solvent. That is, it is a step of extracting an extract (extract) from a plant by adding an appropriate solvent in a state where the content of archigenin is increased by the enzyme conversion step. For example, an appropriate solvent is added to the plant, and the extract is extracted by heating and stirring for an appropriate time. In addition to heating and stirring, the extract can be extracted using any extraction method known to those skilled in the art, such as heating reflux, drip extraction, immersion extraction, or pressure extraction.
アルクチゲニンは水難溶性であることから、有機溶媒を添加することにより、アルクチゲニンの収率を向上させることができる。有機溶媒は、任意の有機溶媒を使用することができる。たとえば、メタノール、エタノールおよびプロパノールなどのアルコール、並びにアセトンを使用することができる。安全性の面を考慮すると、有機溶媒として30%量のエタノールを使用することが好ましい。抽出物から溶媒を留去するとペースト状の濃縮物が得られ、この濃縮物をさらに乾燥すると乾燥物を得ることができる。 Since arctigenin is sparingly soluble in water, the yield of arctigenin can be improved by adding an organic solvent. Any organic solvent can be used as the organic solvent. For example, alcohols such as methanol, ethanol and propanol, and acetone can be used. In view of safety, it is preferable to use 30% amount of ethanol as the organic solvent. When the solvent is distilled off from the extract, a paste-like concentrate is obtained, and when this concentrate is further dried, a dry product can be obtained.
本発明の肝臓の脂肪滴の肥大化抑制剤および肥大化抑制用組成物は、任意の形態の製剤であることができる。肝臓の脂肪滴の肥大化抑制剤および肥大化抑制用組成物は、経口投与製剤として、たとえば糖衣錠、バッカル錠、コーティング錠およびチュアブル錠等の錠剤;トローチ剤;丸剤;散剤;硬カプセル剤および軟カプセル剤を含むカプセル剤;顆粒剤;ならびに懸濁剤、乳剤、シロップ剤およびエリキシル剤等の液剤などであることができる。 The liver fat droplet hypertrophy inhibitor and the hypertrophy inhibitor composition of the present invention can be any form of preparation. An agent for inhibiting enlargement of lipid droplets in the liver and a composition for inhibiting enlargement are, for example, tablets such as sugar-coated tablets, buccal tablets, coated tablets and chewable tablets; troches; pills; powders; hard capsules and Capsules including soft capsules; granules; and liquids such as suspensions, emulsions, syrups and elixirs.
また、本発明の肝臓の脂肪滴の肥大化抑制剤および肥大化抑制用組成物は、静脈注射、皮下注射、腹腔内注射、筋肉内注射、経皮投与、経鼻投与、経肺投与、経腸投与、口腔内投与および経粘膜投与などの非経口投与製剤であることができる。本発明の肝臓の脂肪滴の肥大化抑制剤および肥大化抑制用組成物は、たとえば、注射剤、経皮吸収テープ、エアゾール剤および坐剤などであることができる。 In addition, the agent for suppressing enlargement of lipid droplets of the liver and the composition for suppressing enlargement of the present invention include intravenous injection, subcutaneous injection, intraperitoneal injection, intramuscular injection, transdermal administration, nasal administration, transpulmonary administration, transpulmonary administration. It can be a parenteral preparation such as enteral administration, buccal administration and transmucosal administration. The liver fat droplet hypertrophy inhibitor and the hypertrophy inhibitor composition of the present invention can be, for example, an injection, a transdermal absorption tape, an aerosol, and a suppository.
また、本発明の肝臓の脂肪滴の肥大化抑制剤および肥大化抑制用組成物は、外用剤として提供されることができる。本発明の外用剤は、医薬品および化粧品などであることができる。本発明の外用剤は、皮膚、頭皮、毛髪、粘膜および爪などに適用するための外用剤であることができる。外用剤には、たとえばクリーム剤、軟膏剤、液剤、ゲル剤、ローション剤、乳液剤、エアゾール剤、スティック剤、シートマスク剤、固形剤、泡沫剤、オイル剤およびチック剤等の塗布剤;パップ剤、プラスター剤、テープ剤およびパッチ剤等の貼付剤;並びにスプレー剤などが含まれる。 Moreover, the enlargement inhibitor of fat droplets of the liver and the composition for suppressing enlargement of the present invention can be provided as external preparations. The external preparation of the present invention can be pharmaceuticals and cosmetics. The external preparation of the present invention can be an external preparation for application to skin, scalp, hair, mucous membrane, nails and the like. Examples of external preparations include creams, ointments, liquids, gels, lotions, emulsions, aerosols, sticks, sheet masks, solids, foams, oils, tics, and other coating agents; Adhesives, plasters, adhesives such as tapes and patches; sprays and the like.
また、本発明の肝臓の脂肪滴の肥大化抑制剤および肥大化抑制用組成物は、食用に適した形態であることができ、たとえば固形状、液状、顆粒状、粒状、粉末状、カプセル状、クリーム状およびペースト状などであってもよい。 Further, the lipid fat droplet hypertrophy inhibitor and the hypertrophy suppression composition of the present invention can be in an edible form, for example, solid, liquid, granular, granular, powder, capsule It may be in the form of a cream or paste.
本発明の肥大化抑制用組成物は、医薬品、化粧品および食品などに用いるための組成物であることができる。本発明の肥大化抑制用組成物は、医薬品、化粧品および食品に通常用いられる任意の成分をさらに含むことができる。たとえば、本発明の肥大化抑制用組成物は、薬学的に許容される基剤、担体、賦形剤、結合剤、崩壊剤、滑沢剤および着色剤などをさらに含んでもよい。 The composition for suppressing enlargement of the present invention can be a composition for use in pharmaceuticals, cosmetics, foods and the like. The composition for suppressing enlargement of the present invention can further contain any component usually used in pharmaceuticals, cosmetics and foods. For example, the composition for suppressing enlargement of the present invention may further contain a pharmaceutically acceptable base, carrier, excipient, binder, disintegrant, lubricant, colorant and the like.
肥大化抑制用組成物に使用する担体および賦形剤の例には、乳糖、ブドウ糖、白糖、マンニトール、デキストリン、馬鈴薯デンプン、トウモロコシデンプン、炭酸カルシウム、リン酸カルシウム、硫酸カルシウムおよび結晶セルロースなどを含む。 Examples of carriers and excipients used in the composition for suppressing hypertrophy include lactose, glucose, sucrose, mannitol, dextrin, potato starch, corn starch, calcium carbonate, calcium phosphate, calcium sulfate and crystalline cellulose.
結合剤の例には、デンプン、ゼラチン、シロップ、トラガントゴム、ポリビニルアルコール、ポリビニルエーテル、ポリビニルピロリドン、ヒドロキシプロピルセルロース、メチルセルロース、エチルセルロースおよびカルボキシメチルセルロースなどを含む。 Examples of binders include starch, gelatin, syrup, tragacanth gum, polyvinyl alcohol, polyvinyl ether, polyvinyl pyrrolidone, hydroxypropylcellulose, methylcellulose, ethylcellulose and carboxymethylcellulose.
崩壊剤の例には、デンプン、寒天、ゼラチン末、結晶セルロース、炭酸カルシウム、炭酸水素ナトリウム、アルギン酸ナトリウム、カルボキシメチルセルロースナトリウムおよびカルボキシメチルセルロースカルシウムなどを含む。 Examples of the disintegrant include starch, agar, gelatin powder, crystalline cellulose, calcium carbonate, sodium bicarbonate, sodium alginate, sodium carboxymethyl cellulose, carboxymethyl cellulose calcium and the like.
滑沢剤の例には、ステアリン酸マグネシウム、水素添加植物油、タルクおよびマクロゴールなどを含む。着色剤は、医薬品、化粧品および食品に添加することが許容されている任意の着色剤を使用することができる。 Examples of lubricants include magnesium stearate, hydrogenated vegetable oil, talc and macrogol. As the colorant, any colorant allowed to be added to pharmaceuticals, cosmetics and foods can be used.
また、肥大化抑制用組成物は、必要に応じて、白糖、ゼラチン、精製セラック、ゼラチン、グリセリン、ソルビトール、エチルセルロース、ヒドロキシプロピルセルロース、ヒドロキシプロピルメチルセルロース、ポリビニルピロリドン、フタル酸セルロースアセテート、ヒドロキシプロピルメチルセルロースフタレート、メチルメタクリレートおよびメタアクリル酸重合体などで一層以上の層で被膜してもよい。 In addition, the composition for suppressing enlargement may be sucrose, gelatin, purified shellac, gelatin, glycerin, sorbitol, ethylcellulose, hydroxypropylcellulose, hydroxypropylmethylcellulose, polyvinylpyrrolidone, cellulose acetate phthalate, hydroxypropylmethylcellulose phthalate as necessary. Further, it may be coated with one or more layers such as methyl methacrylate and methacrylic acid polymer.
また、肥大化抑制用組成物は、必要に応じて、pH調節剤、緩衝剤、安定化剤、保存剤、防腐剤、希釈剤、コーティング剤、甘味剤、香料および可溶化剤などを添加してもよい。 In addition, the composition for suppressing enlargement is added with a pH regulator, a buffer, a stabilizer, a preservative, a preservative, a diluent, a coating agent, a sweetener, a fragrance, a solubilizing agent, and the like as necessary. May be.
本発明はまた、本発明の肥大化抑制用組成物を含有する医薬品を提供する。本発明の医薬品は、肝臓の脂肪滴の肥大化を抑制するための医薬品であることができる。また、本発明の医薬品は、脂肪滴肥大に関連する種々の症状を治療、改善および予防するための医薬品であることができ、たとえば脂肪肝並びに脂肪肝に関連する動脈硬化、脂肪性肝炎、肝硬変および肝がんなどの種々の疾患および状態を治療、改善および予防するための医薬品であることができる。 The present invention also provides a pharmaceutical comprising the composition for suppressing enlargement of the present invention. The pharmaceutical of the present invention can be a pharmaceutical for suppressing enlargement of liver lipid droplets. In addition, the medicament of the present invention can be a medicament for treating, ameliorating and preventing various symptoms related to lipid droplet enlargement, for example, fatty liver and arteriosclerosis associated with fatty liver, steatohepatitis, cirrhosis. And pharmaceuticals for treating, ameliorating and preventing various diseases and conditions such as liver cancer.
本発明はまた、アルクチゲニンおよび/またはアルクチインを有効成分として含有する肥大化抑制用食品組成物を提供する。本発明の肥大化抑制用食品組成物は、上述した肥大化抑制剤および肥大化抑制用組成物と同様に構成されることができる。本発明の食品組成物は、脂肪肝並びに脂肪肝に関連する動脈硬化、脂肪性肝炎、肝硬変および肝がんなどの種々の疾患および状態を改善または予防するための食品組成物であることができる。 The present invention also provides a food composition for inhibiting hypertrophy containing architigenin and / or archtiin as active ingredients. The food composition for suppressing enlargement of the present invention can be configured in the same manner as the above-described agent for suppressing enlargement and composition for suppressing enlargement. The food composition of the present invention can be a food composition for improving or preventing various diseases and conditions such as fatty liver and fatty liver-related arteriosclerosis, steatohepatitis, cirrhosis and liver cancer. .
本明細書において「食品組成物」には、一般的な飲食品だけでなく、病者用食品、健康食品、機能性食品、特定保健用食品、栄養補助食品およびサプリメントなどが含まれる。一般的な飲食品には、たとえば各種飲料、各種食品、加工食品、液状食品(スープ等)、調味料、栄養ドリンクおよび菓子類などが含まれる。本明細書において「加工食品」とは、天然の食材(動物および植物など)に対し加工および/または調理を施したものをいい、たとえば肉加工品、野菜加工品、果実加工品、冷凍食品、レトルト食品、缶詰食品、瓶詰食品およびインスタント食品などが含まれる。本発明の食品組成物は、グルカゴンを抑制する旨の表示を付した食品であってもよい。また、本発明の食品組成物は、袋および容器等に封入された形態で提供されてもよい。本発明において使用する袋および容器は、食品に通常使用される任意の袋および容器であることができる。 In the present specification, the “food composition” includes not only general foods and drinks but also foods for patients, health foods, functional foods, foods for specified health use, dietary supplements and supplements. Common foods and drinks include, for example, various beverages, various foods, processed foods, liquid foods (soups, etc.), seasonings, energy drinks, and confectionery. In the present specification, the “processed food” refers to a product obtained by processing and / or cooking natural ingredients (animals, plants, etc.), such as processed meat products, processed vegetable products, processed fruit products, frozen foods, Includes retort foods, canned foods, bottled foods and instant foods. The food composition of the present invention may be a food with an indication that glucagon is suppressed. Moreover, the food composition of the present invention may be provided in a form enclosed in a bag, a container or the like. The bags and containers used in the present invention can be any bags and containers normally used for food.
本発明の肥大化抑制剤、肥大化抑制用組成物および肥大化抑制用食品組成物におけるアルクチゲニンおよび/またはアルクチインの含有量は、脂肪滴の肥大化を抑制する効果を発揮できる量であればよく、適用する対象、目的および投与方法(摂取方法)に応じて適宜設定することができる。たとえばヒトに経口摂取させる場合、好ましくはアルクチゲニンおよび/またはアルクチインを1日あたりの摂取量が10〜2000mgとなるように含むことができる。 The content of arctigenin and / or arctiin in the hypertrophy inhibitor, the hypertrophy suppression composition, and the hypertrophy suppression food composition of the present invention may be any amount that can exert the effect of suppressing the enlargement of fat droplets. Depending on the subject to be applied, purpose and administration method (intake method), it can be set as appropriate. For example, when orally ingested by humans, it is preferable to include archigenin and / or archtiin so that the daily intake is 10 to 2000 mg.
本発明はまた、アルクチゲニンおよび/またはアルクチインを有効成分として含有する、LXRαまたはSREBP1cの発現抑制剤を提供する。LXRαは、肝臓にある核内受容体の1つであり、活性化されるとSREBP1c(Sterol regulatory element-binding protein)の発現を上昇させる、核内転写因子である。SREBP1cは、脂肪酸合成酵素であるFAS(fatty acid synthase)およびACC(acetyl-CoA carboxylase)などの発現を制御する転写因子である。 The present invention also provides an LXRα or SREBP1c expression inhibitor containing arctigenin and / or arctiin as an active ingredient. LXRα is one of the nuclear receptors in the liver and is a nuclear transcription factor that increases the expression of SREBP1c (Sterol regulatory element-binding protein) when activated. SREBP1c is a transcription factor that regulates the expression of fatty acid synthase, such as FAS (fatty acid synthase) and ACC (acetyl-CoA carboxylase).
本明細書において「発現を抑制する」とは、たとえばタンパク質をコードする遺伝子の転写産物の量を減少させることおよびタンパク質の量を減少させることなどを意味する。 As used herein, “suppressing expression” means, for example, decreasing the amount of a transcript of a gene encoding a protein and decreasing the amount of a protein.
本発明のLXRαまたはSREBP1cの発現抑制剤は、アルクチゲニンおよび/またはアルクチインを、ゴボウ、ゴボウシ、ゴボウスプラウトもしくはレンギョウまたはこれらの抽出物として含有してもよい。また、本発明のLXRαまたはSREBP1cの発現抑制剤は、上述した本発明の肥大化抑制剤、肥大化抑制用組成物および肥大化抑制用食品組成物と同様に構成されることができる。 The expression inhibitor of LXRα or SREBP1c of the present invention may contain arctigenin and / or arctiin as burdock, burdock, burdock sprout or forsythia, or an extract thereof. Moreover, the expression inhibitor of LXRα or SREBP1c of the present invention can be configured in the same manner as the enlargement inhibitor, the composition for suppressing enlargement and the food composition for suppressing enlargement of the present invention described above.
本発明のLXRαまたはSREBP1cの発現抑制剤は、LXRαおよび/またはSREBP1cの発現を抑制することにより、脂肪酸合成酵素などの発現を抑制することができる。したがって、本発明のLXRαまたはSREBP1cの発現抑制剤は、肝臓の脂肪滴の肥大化を抑制し、脂肪肝を治療、予防または改善することができる。 The LXRα or SREBP1c expression inhibitor of the present invention can suppress the expression of fatty acid synthase or the like by suppressing the expression of LXRα and / or SREBP1c. Therefore, the LXRα or SREBP1c expression inhibitor of the present invention can suppress the enlargement of liver lipid droplets, and can treat, prevent or improve fatty liver.
以下に実施例を示し、本発明の実施の形態についてさらに詳しく説明するが、本発明は以下の実施例に限定されるものではない。 Hereinafter, examples will be shown and the embodiment of the present invention will be described in more detail. However, the present invention is not limited to the following examples.
(酵素活性の測定)
ゴボウシ中のβ−グルコシダーゼ活性は、以下の方法で測定した。産地やロットが異なるゴボウシをウイレー氏粉砕機により粉砕し、このゴボウシ粉砕品0.1gを10mLの水で希釈し、試料溶液とした。
(Measurement of enzyme activity)
The β-glucosidase activity in burdock was measured by the following method. A burdock of different origin and lot was pulverized by Mr. Willet pulverizer, and 0.1 g of this pulverized burdock was diluted with 10 mL of water to prepare a sample solution.
基質溶液として、p-ニトロフェニル-β-D-グルコピラノシド0.15gに水を加えて25mLに定容し、20mmol/L p-ニトロフェニル-β-D-グルコピラノシド水溶液を調製した。0.1mol/L酢酸緩衝液1mLに20mmol/L p-ニトロフェニル-β-D-グルコピラノシド水溶液0.5mLを加えて、反応混液を調製し、37℃で約5分予備加熱を行った。 As a substrate solution, water was added to 0.15 g of p-nitrophenyl-β-D-glucopyranoside and the volume was adjusted to 25 mL to prepare a 20 mmol / L p-nitrophenyl-β-D-glucopyranoside aqueous solution. A reaction mixture was prepared by adding 0.5 mL of 20 mmol / L p-nitrophenyl-β-D-glucopyranoside aqueous solution to 1 mL of 0.1 mol / L acetate buffer, and pre-heated at 37 ° C. for about 5 minutes.
反応混液に試料溶液0.5mL加えて37℃で15分反応させた後、反応停止液である0.2mol/L炭酸ナトリウム水溶液を2mL加えて反応を停止させた。この液の400nmにおける吸光度を測定し、酵素反応を行わないブランク溶液からの変化量から下式により酵素活性を求めた。
酵素活性(U/g)=(試料溶液の吸光度-ブランク溶液の吸光度)×4mL×1/18.1(p-ニトロフェノールの上記測定条件下でのミリモル分子吸光係数:cm2/μmol)×1/光路長(cm)×1/反応時間(分)×1/0.5mL×1/試料溶液濃度(g/mL)
After adding 0.5 mL of the sample solution to the reaction mixture and reacting at 37 ° C. for 15 minutes, 2 mL of 0.2 mol / L sodium carbonate aqueous solution as a reaction stop solution was added to stop the reaction. The absorbance at 400 nm of this solution was measured, and the enzyme activity was determined from the amount of change from the blank solution in which the enzyme reaction was not performed according to the following formula.
Enzyme activity (U / g) = (absorbance of sample solution−absorbance of blank solution) × 4 mL × 1 / 18.1 (molar molecular extinction coefficient of p-nitrophenol under the above measurement conditions: cm 2 / μmol) × 1 / Optical path length (cm) x 1 / reaction time (min) x 1 / 0.5mL x 1 / sample solution concentration (g / mL)
(実施例1 ゴボウシ抽出物の製造1)
本発明のグルカゴン抑制用組成物の一実施例として、ゴボウシからエキス(抽出物)を抽出した。ゴボウシ(酵素活性8.23U/g)を切裁し、9.5mmの篩を全通するものをさらに0.85mmの篩に通し、75%が残ることを確認した。このゴボウシ細切80kgを29〜33℃に保温した水560Lに加えて30分間攪拌した。次いで、エタノール265Lを加えて85℃に昇温し、さらに60分間加熱還流した。この溶液を遠心分離し、ゴボウシ抽出液を得た。この操作を2回繰り返して得られた抽出液を合わせて、減圧濃縮し、抽出物固形分に対してデキストリン25%量を加えて、噴霧乾燥した。アルクチゲニンおよびアルクチイン含量は、それぞれ6.2%および7.1%であり、アルクチゲニン/アルクチイン(重量比)=0.89のゴボウシ抽出物粉末(デキストリン20%含有)が得られた。
(Example 1 Production of burdock extract 1)
As an example of the composition for suppressing glucagon of the present invention, an extract (extract) was extracted from a gobo cow. The burdock (enzyme activity 8.23 U / g) was cut, and the whole 9.5 mm sieve was passed through a 0.85 mm sieve to confirm that 75% remained. 80 kg of this burdock slice was added to 560 L of water kept at 29-33 ° C. and stirred for 30 minutes. Next, 265 L of ethanol was added, the temperature was raised to 85 ° C., and the mixture was further heated to reflux for 60 minutes. This solution was centrifuged to obtain a burdock extract. Extracts obtained by repeating this operation twice were combined, concentrated under reduced pressure, added with a 25% amount of dextrin based on the solid content of the extract, and spray-dried. The contents of arctigenin and arcthiin were 6.2% and 7.1%, respectively, and a burdock extract powder (containing 20% dextrin) having an arctigenin / arctiin (weight ratio) = 0.89 was obtained.
(実施例2 ゴボウシ抽出物の製造2)
本発明のグルカゴン抑制用組成物の一実施例として、ゴボウシからエキス(抽出物)を抽出した。ゴボウシ(酵素活性8.23U/g)を切裁し、9.5mmの篩を全通するものをさらに0.85mmの篩に通し、75%が残ることを確認した。このゴボウシ細切80kgを30〜33℃に保温した水560Lに加えて30分間攪拌した後、エタノール265Lを加えて85℃に昇温し、さらに30分間加熱還流した。この溶液を遠心分離し、ゴボウシ抽出液を得た。この操作を2回繰り返して得られた抽出液を合わせて、減圧濃縮し、抽出物固形分に対してデキストリン25%量を加えて、噴霧乾燥した。アルクチゲニンおよびアルクチイン含量は、それぞれ6.0%および6.8%であり、アルクチゲニン/アルクチイン(重量比)=0.87のゴボウシ抽出物粉末(デキストリン20%含有)が得られた。
(Example 2 Production of burdock extract 2)
As an example of the composition for suppressing glucagon of the present invention, an extract (extract) was extracted from a gobo cow. The burdock (enzyme activity 8.23 U / g) was cut, and the whole 9.5 mm sieve was passed through a 0.85 mm sieve to confirm that 75% remained. After adding 80 kg of this burdock chopped to 560 L of water kept at 30 to 33 ° C. and stirring for 30 minutes, 265 L of ethanol was added, the temperature was raised to 85 ° C., and the mixture was further heated to reflux for 30 minutes. This solution was centrifuged to obtain a burdock extract. Extracts obtained by repeating this operation twice were combined, concentrated under reduced pressure, added with a 25% amount of dextrin based on the solid content of the extract, and spray-dried. Arctigenin and arcthiin contents were 6.0% and 6.8%, respectively, and burdock extract powder (containing 20% dextrin) having an arctigenin / arctiin (weight ratio) = 0.87 was obtained.
(実施例3 ゴボウシ抽出物の製造3)
本発明のグルカゴン抑制用組成物の一実施例として、ゴボウシからエキス(抽出物)を抽出した。ゴボウシ(酵素活性7.82U/g)を切裁し、9.5mmの篩を全通するものをさらに0.85mmの篩に通し、75%が残ることを確認した。このゴボウシ細切80kgを30〜32℃に保温した水560Lに加えて40分間攪拌した後、60分後にエタノール258Lを加えて85℃に昇温し、さらに30分間加熱還流した。この液を遠心分離し、ゴボウシ抽出液を得た。この操作を2回繰り返して得られた抽出液を合わせて、減圧濃縮し、抽出物固形分に対してデキストリン25%量を加えて、噴霧乾燥した。アルクチゲニンおよびアルクチイン含量は、それぞれ6.2%および6.7%であり、アルクチゲニン/アルクチイン(重量比)=0.93のゴボウシ抽出物粉末(デキストリン20%含有)が得られた。
(Example 3 Production of burdock extract 3)
As an example of the composition for suppressing glucagon of the present invention, an extract (extract) was extracted from a gobo cow. The burdock (enzyme activity: 7.82 U / g) was cut, and all the 9.5 mm sieve was passed through the 0.85 mm sieve to confirm that 75% remained. This burdock 80 kg was added to 560 L of water kept at 30 to 32 ° C. and stirred for 40 minutes, and then 60 minutes later, 258 L of ethanol was added, the temperature was raised to 85 ° C., and the mixture was further refluxed for 30 minutes. This solution was centrifuged to obtain a burdock extract. Extracts obtained by repeating this operation twice were combined, concentrated under reduced pressure, added with a 25% amount of dextrin based on the solid content of the extract, and spray-dried. Arctigenin and arctiin contents were 6.2% and 6.7%, respectively, and an argotigenin / arctiin (weight ratio) = 0.93 burdock extract powder (containing 20% dextrin) was obtained.
(実施例4 ゴボウシ抽出物の製造4)
本発明のグルカゴン抑制用組成物の一実施例として、ゴボウシからエキス(抽出物)を抽出した。ゴボウシ(酵素活性7.82U/g)を切裁し、9.5mmの篩を全通するものをさらに0.85mmの篩に通し、75%が残ることを確認した。このゴボウシ細切80kgを30〜32℃に保温した水560Lに加えて30分間攪拌した後、エタノール253Lを加えて85℃に昇温し、さらに40分間加熱還流した。この液を遠心分離し、得られた抽出液を得た。この操作を2回繰り返して得られた抽出液を合わせて、減圧濃縮し、抽出物固形分に対してデキストリン25%量を加えて、噴霧乾燥した。アルクチゲニンおよびアルクチイン含量は、それぞれ6.4%および7.2%であり、アルクチゲニン/アルクチイン(重量比)=0.89のゴボウシ抽出物粉末(デキストリン20%含有)が得られた。
(Example 4 Production of burdock extract 4)
As an example of the composition for suppressing glucagon of the present invention, an extract (extract) was extracted from a gobo cow. The burdock (enzyme activity: 7.82 U / g) was cut, and all the 9.5 mm sieve was passed through the 0.85 mm sieve to confirm that 75% remained. After adding 80 kg of this burdock chopped to 560 L of water kept at 30 to 32 ° C. and stirring for 30 minutes, ethanol 253 L was added, the temperature was raised to 85 ° C., and the mixture was further heated to reflux for 40 minutes. This liquid was centrifuged to obtain the resulting extract. Extracts obtained by repeating this operation twice were combined, concentrated under reduced pressure, added with a 25% amount of dextrin based on the solid content of the extract, and spray-dried. Arctigenin and arctiin contents were 6.4% and 7.2%, respectively, and burdock extract powder (containing 20% dextrin) having arctigenin / arctiin (weight ratio) = 0.89 was obtained.
(実施例5 シナレンギョウ葉抽出物の製造1)
本発明のグルカゴン抑制用組成物の一実施例として、シナレンギョウ葉からエキス(抽出物)を抽出した。アルクチイン2.53%およびアルクチゲニン0.76%を含有するレンギョウ葉小刻み50gに水350mLを加えて37℃で30分間保温後、エタノール150mLを添加し30分間加熱抽出した。この溶液を100メッシュ篩を用いて固液分離し、凍結乾燥を行うことにより、アルクチゲニン含量が5.62%のシナレンギョウ葉抽出物18.62gを得た。
(Example 5 Production of Synaxenix leaf extract 1)
As an example of the glucagon-suppressing composition of the present invention, an extract (extract) was extracted from Sinalengyo leaves. 350 mL of water was added to 50 g of forsythia leaf chopping containing 2.53% of arctiin and 0.76% of arctigenin, and the mixture was incubated at 37 ° C. for 30 minutes, and then 150 mL of ethanol was added and extracted by heating for 30 minutes. This solution was subjected to solid-liquid separation using a 100-mesh sieve and freeze-dried to obtain 18.62 g of Sinalengyo leaf extract having an arctigenin content of 5.62%.
(実施例6 シナレンギョウ葉抽出物の製造2)
本発明のグルカゴン抑制用組成物の一実施例として、シナレンギョウ葉からエキス(抽出物)を抽出した。アルクチイン7.38%およびアルクチゲニン0.78%を含有するレンギョウ葉小刻み720gに水5Lを加えて37°Cで30分間保温後、エタノール2.16Lを添加し30分間加熱抽出した。この溶液を100メッシュ篩を用いて固液分離し、凍結乾燥を行うことにより、アルクチゲニン含量が9.55%のシナレンギョウ葉抽出物343.07gを得た。
(Example 6: Production of Sinalengyo leaf extract 2)
As an example of the glucagon-suppressing composition of the present invention, an extract (extract) was extracted from Sinalengyo leaves. 5 L of water was added to 720 g of forsythia leaf chopping containing 7.38% arctiin and 0.78% arctigenin, and incubated at 37 ° C for 30 minutes, followed by addition of 2.16 L of ethanol and extraction by heating for 30 minutes. This solution was subjected to solid-liquid separation using a 100 mesh sieve and freeze-dried to obtain 343.07 g of Sinalengyo leaf extract having 9.55% arctigenin content.
(実施例7 ゴボウシ抽出物粉末配合顆粒剤)
本発明のグルカゴン抑制用組成物の一実施例として、ゴボウシ抽出物を用いて顆粒剤を製造した。「日局」製剤総則、顆粒剤の項に準じて顆粒剤を製造した。すなわち、下記(1)〜(3)の成分をとり、顆粒状に製した。これを1.5gずつアルミラミネートフィルムに充填し、1包あたりゴボウシ抽出物粉末を0.5g含有する顆粒剤を得た。
(Example 7 granule containing burdock extract powder)
As an example of the composition for suppressing glucagon of the present invention, a granule was produced using a gobo cow extract. Granules were produced in accordance with the “Japan Pharmacopoeia” general rules for preparations and granules. That is, the following components (1) to (3) were taken and made into granules. This was filled into an aluminum laminate film in an amount of 1.5 g to obtain granules containing 0.5 g of burdock extract powder per packet.
(1)実施例2のゴボウシ抽出物粉末 33.3%
(2)乳糖 65.2%
(3)ヒドロキシプロピルセルロース 1.5%
合計 100%
(1) Gobo cow extract powder of Example 2 33.3%
(2) Lactose 65.2%
(3) Hydroxypropylcellulose 1.5%
Total 100%
(実施例8 ゴボウシ抽出物粉末配合顆粒剤)
本発明のグルカゴン抑制用組成物の一実施例として、ゴボウシ抽出物を用いて顆粒剤を製造した。「日局」製剤総則、顆粒剤の項に準じて顆粒剤を製造した。すなわち、下記(1)〜(3)の成分をとり、顆粒状に製した。これを3.0gずつアルミラミネートフィルムに充填し、1包あたりゴボウシ抽出物粉末を2g含有する顆粒剤を得た。
(Example 8 granule containing burdock extract powder)
As an example of the composition for suppressing glucagon of the present invention, a granule was produced using a gobo cow extract. Granules were produced in accordance with the “Japan Pharmacopoeia” general rules for preparations and granules. That is, the following components (1) to (3) were taken and made into granules. Each 3.0 g of this was filled in an aluminum laminate film to obtain granules containing 2 g of burdock extract powder per packet.
(1)実施例2のゴボウシ抽出物粉末 66.7%
(2)乳糖 30.3%
(3)ヒドロキシプロピルセルロース 3.0%
合計 100%
(1) Gobo cow extract powder of Example 2 66.7%
(2) Lactose 30.3%
(3) Hydroxypropylcellulose 3.0%
Total 100%
(実施例9 ゴボウシ抽出物粉末配合錠剤)
本発明のグルカゴン抑制用組成物の一実施例として、ゴボウシ抽出物を用いて錠剤を製造した。「日局」製剤総則、錠剤の項に準じて錠剤を製した。すなわち、下記(1)〜(6)の成分をとり、錠剤を得た。
Example 9 Tablets containing burdock extract powder
As one example of the glucagon-suppressing composition of the present invention, tablets were produced using a gobo cow extract. Tablets were produced in accordance with the “Japanese Pharmacopoeia” General Rules for Preparations and Tablets. That is, the following components (1) to (6) were taken to obtain tablets.
(1)実施例2のゴボウシ抽出物粉末 37.0%
(2)結晶セルロース 45.1%
(3)カルメロースカルシウム 10.0%
(4)クロスポピドン 3.5%
(5)含水二酸化ケイ素 3.4%
(6)ステアリン酸マグネシウム 1.0%
合計 100%
(1) Burdock extract powder of Example 2 37.0%
(2) Crystalline cellulose 45.1%
(3) Carmellose calcium 10.0%
(4) Crospopidone 3.5%
(5) Hydrous silicon dioxide 3.4%
(6) Magnesium stearate 1.0%
Total 100%
(実施例10 肝臓の脂肪滴に対するアルクチゲニンの効果)
[実験動物]
レプチン受容体欠損モデルである、5週齢の雄性db/dbマウス(BKS.Cg-+Leprdb/+Leprdb/Jcl、日本クレア社より購入)を使用して、1週間の予備飼育後に実験を開始した。動物は温度23.0±5℃、湿度50.0±10%、12時間の明暗サイクルの環境下で飼育した。動物実験は慶應義塾大学動物実験委員会の承認を得て、慶應義塾大学動物実験規定に基づき実施した。
(Example 10 Effect of arctigenin on liver lipid droplets)
[Experimental animals]
Using a leptin receptor-deficient model, a 5-week-old male db / db mouse (BKS.Cg- + Leprdb / + Leprdb / Jcl, purchased from CLEA Japan) did. The animals were kept in an environment of a temperature of 23.0 ± 5 ° C., a humidity of 50.0 ± 10%, and a 12 hour light / dark cycle. Animal experiments were approved by the Animal Experiment Committee of Keio University and conducted based on the Keio University Animal Experiment Rules.
[実験方法]
予備飼育後に、マウスを(a)Control群および(b)アルクチゲニン投与群(AG群)の2群にわけ(各群n=8)、Control群には精製飼料(AIN-93G)を、AG群にはアルクチゲニン(>98.0%)0.2%配合の精製飼料を9週間自由摂取させた。投与6週目に尾静脈より採血を行い、血中TGおよび血中飽和脂肪酸濃度を測定した。投与終了後、18時間の絶食を行い、麻酔下で腹部大静脈より採血し、肝臓を採取した。採取した肝臓は一部を遺伝子解析用、一部を組織切片用に分けた。
[experimental method]
After preliminary breeding, the mice were divided into two groups (n) (a) Control group and (b) architigenin administration group (AG group) (each group n = 8), and purified feed (AIN-93G) was added to the Control group, AG group Was allowed free intake of refined feed containing 0.2% arguchigenin (> 98.0%) for 9 weeks. Six weeks after administration, blood was collected from the tail vein, and blood TG and blood saturated fatty acid concentrations were measured. After the administration, the animals were fasted for 18 hours, and blood was collected from the abdominal vena cava under anesthesia, and the liver was collected. The collected liver was partly divided for gene analysis and partly for tissue section.
[血中脂質の測定]
血中のトリグリセリド(TG)および遊離脂肪酸の濃度は、それぞれ、デタミナーL TGII(協和メデックス株式会社製)およびNEFA C-テストワコー(和光純薬工業株式会社製)を用いて測定した。
[Measurement of blood lipids]
The concentrations of triglyceride (TG) and free fatty acid in the blood were measured using Determiner L TGII (manufactured by Kyowa Medex Co., Ltd.) and NEFA C-Test Wako (manufactured by Wako Pure Chemical Industries, Ltd.), respectively.
図1は、各群の血中TG濃度(mg/dL)を示す。また、図2は、各群の血中遊離脂肪酸濃度(μEq/L)を示す。図1および図2における値は、6匹の平均±標準誤差(Mean±S.E.M)を表す。Student’s t-testの結果、p値が0.05より小さい場合には「*」を付した。図1および図2に示すように、AG群では、Control群と比較して血中TG濃度および血中遊離脂肪酸濃度が有意に低かった。 FIG. 1 shows the blood TG concentration (mg / dL) in each group. FIG. 2 shows the blood free fatty acid concentration (μEq / L) in each group. The values in FIGS. 1 and 2 represent the mean ± standard error (Mean ± S.E.M) of 6 animals. As a result of Student ’s t-test, “*” was added when the p-value was less than 0.05. As shown in FIGS. 1 and 2, in the AG group, the blood TG concentration and the blood free fatty acid concentration were significantly lower than those in the Control group.
[肝臓における脂肪滴蓄積]
Control群およびAG群の肝臓組織を10%ホルマリン液により固定後、組織切片を作製し顕微鏡下で観察した。図3はControl群、図4はAG群の肝臓組織の顕微鏡画像を表す図である。図3および図4に示すように、AG群では、Control群と比較して脂肪滴が小さく、また数が少なかった。
[Liquid droplet accumulation in the liver]
After fixing the liver tissues of the Control group and the AG group with 10% formalin solution, tissue sections were prepared and observed under a microscope. FIG. 3 is a view showing a microscope image of the liver tissue of the Control group, and FIG. 4 is a view of the AG group. As shown in FIGS. 3 and 4, in the AG group, the number of lipid droplets was smaller and the number was smaller than that in the Control group.
次に、各個体についてランダムに5枚の画像を取得し、画像解析ソフトImageJを用いて各群の肝臓組織における脂肪滴数、脂肪滴面積および各個体中の最大サイズの脂肪滴面積を測定した。図5は各群の肝臓組織における30μm2より大きい脂肪滴数を示す。図6は、各群の肝臓組織における脂肪滴面積の平均値(μm2)を示す。図7は、各群の肝臓組織における最大サイズの脂肪滴面積の平均値(μm2)を示す。AG群における脂肪滴数、脂肪滴面積の平均値および各個体中の最大サイズの脂肪滴面積の平均値はいずれも、Control群と比較して低かった。 Next, five images were randomly acquired for each individual, and the number of lipid droplets, the lipid droplet area, and the maximum size of the lipid droplet area in each individual were measured using image analysis software ImageJ. . FIG. 5 shows the number of lipid droplets greater than 30 μm 2 in the liver tissue of each group. FIG. 6 shows the average value (μm 2 ) of the lipid droplet area in the liver tissue of each group. FIG. 7 shows the average value (μm 2 ) of the largest lipid droplet area in the liver tissue of each group. The number of lipid droplets in the AG group, the average value of the lipid droplet area, and the average value of the maximum size lipid droplet area in each individual were all lower than those in the Control group.
これらの結果から、アルクチゲニンは、肝臓において脂肪滴の肥大化を抑制する作用を有することが示唆された。 From these results, it was suggested that arctigenin has an action of suppressing fat droplet enlargement in the liver.
[脂肪酸合成関連遺伝子の発現量]
各群について、得られた臓器からtotal RNAの抽出およびcDNA合成を行った後、qPCRにより脂肪酸合成関連遺伝子であるSREBP1c、FAS、LXRαおよびACCをコードする遺伝子の発現量を比較した。コントロールとして、18S rRNAを用いた。qPCRのためのプライマーは、18S(F: TTCTGGCCAACGGTCTAGACAAC(配列番号1)、R: CCAGTGGTCTTGGTGTGCTGA(配列番号2))、SREBP1c(F: GGTACCTGCGGGACAGCTTA(配列番号3)、R: CCGTGAGCTACCTGGACTGAA(配列番号4))、FAS(F: CTGGAGGCCTTGCCACTGTA(配列番号5)、R: GCTTGCACCAACACTCAGTTGAC(配列番号6))、LXRα(F: CTGGAGACGTCACGGAGGTACA(配列番号7)、R: TGATGGCAATGAGCAGAGCA(配列番号8))、ACC(F: ACCAACTCCACTGTTTGTGA(配列番号9)、R: CCTTGGAATTCAGGAGAGGA(配列番号10))を用いた。
[Expression level of fatty acid synthesis-related genes]
For each group, total RNA was extracted from the obtained organ and cDNA synthesis was performed, and then the expression levels of genes encoding fatty acid synthesis-related genes SREBP1c, FAS, LXRα and ACC were compared by qPCR. As a control, 18S rRNA was used. Primers for qPCR are 18S (F: TTCTGGCCAACGGTCTAGACAAC (SEQ ID NO: 1), R: CCAGTGGTCTTGGTGTGCTGA (SEQ ID NO: 2)), SREBP1c (F: GGTACCTGCGGGACAGCTTA (SEQ ID NO: 3), R: CCGTGAGCTACCTGGACTGAA (SEQ ID NO: 4)), FAS (F: CTGGAGGCCTTGCCACTGTA (SEQ ID NO: 5), R: GCTTGCACCAACACTCAGTTGAC (SEQ ID NO: 6)), LXRα (F: CTGGAGACGTCACGGAGGTACA (SEQ ID NO: 7), R: TGATGGCAATGAGCAGAGCA (SEQ ID NO: 8)), ACC (F: ACCAACTCCACTGTTTGTGA ), R: CCTTGGAATTCAGGAGAGGA (SEQ ID NO: 10)).
図8はControl群およびAG群におけるSREBP1c、FAS、LXRαおよびACCの発現量を示す。図8における値は、6匹の平均±標準誤差(Mean±S.E.M)を表す。Student’s t-testの結果、p値が0.01より小さい場合には「**」を付した。AG群では、Control群と比較していずれの遺伝子の発現量も低く、SREBP1cに関しては有意に低かった。 FIG. 8 shows the expression levels of SREBP1c, FAS, LXRα and ACC in the Control group and the AG group. The values in FIG. 8 represent the mean ± standard error (Mean ± S.E.M) of 6 animals. As a result of Student ’s t-test, “**” was added when the p-value was smaller than 0.01. In the AG group, the expression level of any gene was low compared to the Control group, and SREBP1c was significantly lower.
これらの結果から、アルクチゲニンは、SREBP1c、FAS、LXRαおよびACCをコードする遺伝子の発現を抑制する作用を有することが示された。 From these results, it was shown that arctigenin has an action of suppressing the expression of genes encoding SREBP1c, FAS, LXRα and ACC.
本発明は、肝臓における脂肪滴の肥大化を抑制することができるため、脂肪肝や、脂肪肝に由来する様々な生活習慣病、肝硬変および肝がんなどを治療、予防または改善するための医薬品および食品などに利用可能である。 The present invention can suppress the enlargement of lipid droplets in the liver, and therefore, a pharmaceutical product for treating, preventing or improving fatty liver, various lifestyle-related diseases derived from fatty liver, cirrhosis and liver cancer, etc. And can be used for foods.
Claims (6)
An expression inhibitor of LXRα or SREBP1c, which contains arctigenin and / or arctiin as an active ingredient.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2017050740A JP7478504B2 (en) | 2017-03-16 | 2017-03-16 | Inhibitor of enlargement of lipid droplets in the liver, composition for inhibiting enlargement of lipid droplets in the liver, and food composition for inhibiting enlargement of lipid droplets in the liver |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2017050740A JP7478504B2 (en) | 2017-03-16 | 2017-03-16 | Inhibitor of enlargement of lipid droplets in the liver, composition for inhibiting enlargement of lipid droplets in the liver, and food composition for inhibiting enlargement of lipid droplets in the liver |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2018154569A true JP2018154569A (en) | 2018-10-04 |
JP7478504B2 JP7478504B2 (en) | 2024-05-07 |
Family
ID=63716037
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2017050740A Active JP7478504B2 (en) | 2017-03-16 | 2017-03-16 | Inhibitor of enlargement of lipid droplets in the liver, composition for inhibiting enlargement of lipid droplets in the liver, and food composition for inhibiting enlargement of lipid droplets in the liver |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP7478504B2 (en) |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2008297209A (en) * | 2007-05-29 | 2008-12-11 | Yomeishu Seizo Co Ltd | Lipid metabolism-improving composition |
KR20140146407A (en) * | 2013-06-17 | 2014-12-26 | 한국 한의학 연구원 | A composition for preventing or treating fatty liver disease or obesity, comprising a extract of Arctium lappa Linne, Glycyrrhiza uralensis Fischer, Zingiberis rhizoma Crudus and Magnoliae Cortex |
-
2017
- 2017-03-16 JP JP2017050740A patent/JP7478504B2/en active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2008297209A (en) * | 2007-05-29 | 2008-12-11 | Yomeishu Seizo Co Ltd | Lipid metabolism-improving composition |
KR20140146407A (en) * | 2013-06-17 | 2014-12-26 | 한국 한의학 연구원 | A composition for preventing or treating fatty liver disease or obesity, comprising a extract of Arctium lappa Linne, Glycyrrhiza uralensis Fischer, Zingiberis rhizoma Crudus and Magnoliae Cortex |
Non-Patent Citations (5)
Title |
---|
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, vol. 412, JPN6022005768, 2011, pages 197 - 202, ISSN: 0004704827 * |
INTERNATIONAL JOURNAL OF BIOLOGICAL SCIENCES, vol. 13, no. 3, JPN6022005767, 25 February 2017 (2017-02-25), pages 349 - 357, ISSN: 0004704826 * |
NUTRIENTS, vol. 7, JPN6021000785, 2015, pages 2440 - 2455, ISSN: 0004704823 * |
NUTRITION RESEARCH AND PRACTICE, vol. 8, no. 6, JPN6021000784, 2014, pages 655 - 661, ISSN: 0004704824 * |
SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, vol. 46(11), JPN6021028201, 2011, pages 1381 - 1388, ISSN: 0004704825 * |
Also Published As
Publication number | Publication date |
---|---|
JP7478504B2 (en) | 2024-05-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5937596B2 (en) | Urushi extract with increased content of active flavonoid compound and method for producing the same | |
US20100210722A1 (en) | Composition for preventing or treating lipid metabolic disorders comprising fucoxanthin or marine plant extract containing same | |
AU2018203677A1 (en) | Modified polyphenol compositions | |
TW201219360A (en) | Heat shock protein expression inducer | |
JP6161438B2 (en) | Fat accumulation inhibitor and / or fat accumulation reducing agent | |
WO2017008909A1 (en) | Oral formulation comprising berberine and morus alba extract | |
JP4974553B2 (en) | Acetaldehyde metabolism promoter | |
JP2008231057A (en) | Composition for controlling absorption of neutral fat | |
JP5775922B2 (en) | Xanthine oxidase inhibitor and uric acid production inhibitor | |
JP2018154569A (en) | Agent for suppressing enlargement of lipid droplets in liver, composition for suppressing enlargement of lipid droplets in liver and food composition for suppressing enlargement of fat droplets in liver | |
JP2011012021A (en) | Blood sugar-controlling composition | |
JP2007230987A (en) | Anti-obestic agent | |
JP7083420B2 (en) | Glucagon inhibitor, glucagon inhibitor composition and glucagon inhibitor food composition | |
JP2019210278A (en) | Composition for reducing cholesterol, and method for imparting cholesterol reducing functionality | |
JP5969308B2 (en) | Nitric oxide secretion promoter or secretion inducer of vascular endothelial cells | |
WO2018168333A1 (en) | Bile acid synthesis promoter, composition for promoting bile acid synthesis and food composition for promoting bile acid synthesis | |
JP5706142B2 (en) | Blood glucose lowering agent, visceral fat accumulation inhibitor, TG lowering agent, faecal fat excretion promoter containing ethanol extract of Fuyubodaiju flower as an active ingredient | |
JP6861139B2 (en) | Serotonin metabolism inhibitors, food and drink compositions, and pharmaceuticals | |
JP2022135271A (en) | Blood-triglyceride-level rise inhibitor | |
JP2010241792A (en) | Lipase inhibitor, and food and drink | |
JP2006022002A (en) | Nitrogen monoxide production inhibitory composition and chronic arthritis inhibitory composition | |
JP2009269895A (en) | Drug-induced liver disorder inhibitory composition | |
CN114073717A (en) | Application of inonotus obliquus extract in reducing homocysteine | |
JP2021016363A (en) | Fat decomposition accelerator, food product containing the same, and processed food product for fat decomposition accelerator | |
JP2021054762A (en) | Blood pressure elevation inhibitor, food additive, and food and drink |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20200205 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20201225 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20210118 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20210318 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20210719 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20220214 |
|
C60 | Trial request (containing other claim documents, opposition documents) |
Free format text: JAPANESE INTERMEDIATE CODE: C60 Effective date: 20220516 |
|
C116 | Written invitation by the chief administrative judge to file amendments |
Free format text: JAPANESE INTERMEDIATE CODE: C116 Effective date: 20220530 |
|
C22 | Notice of designation (change) of administrative judge |
Free format text: JAPANESE INTERMEDIATE CODE: C22 Effective date: 20220530 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230904 |
|
A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A712 Effective date: 20231218 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20240422 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 7478504 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |